Facial aesthetic injections in clinical practice: Pretreatment and posttreatment consensus recommendations to minimise adverse outcomes. (22nd March 2020)

• Record Type: Journal Article
• Authors: Goodman, Greg J.; Liew, Steven; Callan, Peter; Hart, Sarah
• Is Part Of: Australasian journal of dermatology. Volume 61:Number 3(2020)
• Page Start: 217
• Page End: 225
• Publication Date: 2020-03-22
• Subjects: botulinum toxin -- dermal fillers -- hyaluronic acid -- neuromodulators -- rejuvenation; Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.13273
• Languages: English
• ISSNs: 0004-8380

Abstract

Abstract: Facial aesthetic treatment with injectable neuromodulators and hyaluronic acid fillers is well established, with favourable safety profiles and consistent outcomes. As with any medical treatment, adverse events and complications may occur. Adverse events associated with these products are typically transient and mild to moderate in severity. Serious adverse events, such as infection and intravascular occlusion, are rare. Proper patient selection, consent and counselling, preparation and impeccable injection technique are important risk reduction strategies. Both clinicians and patients must be alert to the signs and symptoms of complications so that appropriate treatment can be started promptly. In this article, the authors review the current literature and provide their consensus recommendations for minimising adverse outcomes when treating patients with botulinum toxin or hyaluronic acid fillers.